Charter earns CE approval for cryogenic stem cell storage containers
Charter Medical, a subsidiary of Lydall, has received CE Mark approval on its next generation Cell Freeze Cryogenic Storage Containers for Hematopoietic Progenitor Cells (HPCs).
The European approval enables Charter Medical to begin marketing and selling the newly designed and expanded product offering for cryogenic storage, preservation, and transfer of HPCs in Europe.
The storage containers which are said to be durable offer a size range from 50 mL to 750 mL when frozen at ultralow (-196*C) temperatures.
Lydall CEO Dale Barnhart said the launch of the product into Europe represents a strategic growth opportunity for the Cell-Freeze product line.
"It demonstrates our commitment to increase our presence globally in the biotech and cellular therapy markets," Barnhart added.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs